18 completed, 12 recruiting, 12 terminated, 3 not yet recruiting. 27 Phase 2, 12 Phase 1, 11 Not applicable, 2 Phase 3, 1 Early Phase 1.
Follow Cancer of the Breast: new trials by email Literature Review of Cancer of the Breast trials Research Report on Cancer of the Breast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity 68Ga-Galmydar, PET/MRI, 18F-FDG - Lymphoma Cancer, Breast Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 36 | 2026-11-01 | 2026-09-24 |
| Overcoming Racial Disparities in Screening Mammography Appointment mail reminder, Telephone counseling, Digital navigation video - Breast Cancer, Cancer of the Breast | Not applicable | Not yet recruiting | Washington University School of Medicine | 176 | 2026-10-31 | 2026-08-12 |
| Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases Arm 1 - Breast Cancer, Breast Carcinoma | Recruiting | National Cancer Institute (NCI) | 139 | 2026-10-29 | 2026-10-26 | |
| Precision Supplemental Imaging in Women With Dense Breasts Prognosia Breast, Mammogram, MRI - Breast Cancer, Cancer of the Breast | Not applicable | Recruiting | Washington University School of Medicine | 78 | 2026-09-09 | 2026-09-16 |
| A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast) Expression Networks for highLIGHting Tumor vulnerabilities (ENLIGHT), TruSight(R) Oncology 500, TruSeq Matched Tumor Normal Whole Exome Sequencing Assay - Breast Cancer, Breast Carcinoma | Not applicable | Recruiting | National Cancer Institute (NCI) | 175 | 2026-02-23 | 2026-08-21 |
| Breast Re-irradiation After Second Ipsilateral Lumpectomy Intensity modulated radiation therapy (IMRT) - Breast Cancer, Cancer | Not applicable | Recruiting | Youssef Zeidan | 114 | 2025-10-27 | 2025-11-13 |
| Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder Psilocybin therapy - Adjustment Disorder, Adjustment Disorder With Anxious Mood | Phase 2 | Recruiting | Psyence Australia Pty Ltd | 87 | 2025-10-01 | 2026-03-03 |
| ChatGPT & Surgeon Synergy: Redefining Breast Reconstruction Consultations for Enhanced Patient Engagement and Satisfaction ChatGPT-generated patient education, Usual patient education - Breast Cancer, Cancer of the Breast | Not applicable | Recruiting | Washington University School of Medicine | 410 | 2025-06-03 | 2026-06-10 |
| DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY Tango - Cancer of the Breast, Chemotherapy-induced Neuropathy | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 140 | 2025-02-19 | 2026-10-09 |
| Vocorder Device Validation in Clinical Settings - Continuous Monitoring of Individuals (Vocorder Clinical Validation-VCV) Cancer of the Breast, Cancer of Stomach | Not yet recruiting | Mitera Hospital | 515 | 2024-12-09 | 2024-12-02 | |
| NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based Prosigna breast cancer gene signature assay - Breast Cancer, Cancer of the Breast | Phase 2 | Recruiting | Washington University School of Medicine | 81 | 2024-05-30 | 2026-04-13 |
| A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer BC1 cell line, Bria-OTS regimen and CPI (tislelizumab), Bria-OTS regimen and CPI (tislelizumab) expansion cohort - Breast Cancer, Breast Tumor | Phase 1 / Phase 2 | Unknown | BriaCell Therapeutics Corporation | 18 | 2024-05-29 | 2024-08-26 |
| COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients Cryoablation - Breast Cancer, Cancer of the Breast | Recruiting | Washington University School of Medicine | 100 | 2023-07-26 | 2026-05-07 | |
| Prehabilitation to Revolutionize Oncology: Telehealth Exercise for Cognitive Triumphs (The PROTECT Trial) Physical Activity Intervention - Breast Cancer, Cancer of the Breast | Not applicable | Completed | Washington University School of Medicine | 41 | 2023-05-11 | 2025-08-28 |
| Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC NUV-422, Fulvestrant - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | Withdrawn | Nuvation Bio Inc. | 2022-09-01 | 2023-07-11 | |
| NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors NUV-868, Olaparib, Enzalutamide - Advanced Solid Tumor, Ovarian Cancer | Phase 1 | Terminated | Nuvation Bio Inc. | 82 | 2022-03-29 | 2025-11-06 |
| Mental and Cognitive Health and Physical Activity in the Perioperative Breast Cancer Setting Actigraph, Questionnaires, BrainBaseline application - Breast Cancer, Breast Neoplasms | Completed | Washington University School of Medicine | 42 | 2022-03-10 | 2024-09-19 | |
| Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing DiviTum® TKa assay, Study Care Plans - Breast Cancer, Cancer of the Breast | Not applicable | Recruiting | Washington University School of Medicine | 55 | 2022-03-07 | 2026-07-06 |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors NUV-422 - Glioma, Glioma, Malignant | Phase 1 | Terminated | Nuvation Bio Inc. | 74 | 2020-12-08 | 2023-07-14 |
| Real-time Intraoperative Breast Cancer Visualization for Margin Assessment LS301, Cancer Vision Goggles and standard fluorescence imaging systems, Surgery - Breast Cancer, Cancer of the Breast | Phase 1 / Phase 2 | Terminated | Samuel Achilefu | 9 | 2020-02-18 | 2025-08-17 |
Showing 20 of 50. Sign in to see all of them.
Breast Neoplasms (50) · Triple Negative Breast Neoplasms (6) · Neoplasms (4) · Pancreatic Neoplasms (3) · Prostatic Neoplasms (3) · Kidney Neoplasms (2) · Melanoma (2) · Motor Activity (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms, Castration-Resistant (2) · Stomach Neoplasms (2) · Adjustment Disorders (1) · Breast Neoplasms, Male (1) · Carcinoma, Ductal (1) · Carcinoma, Non-Small-Cell Lung (1)
Breast Diseases (50) · Neoplasms by Site (50) · Skin Diseases (50) · Skin and Connective Tissue Diseases (50) · Neoplasms (46) · Male Urogenital Diseases (5) · Neoplasms by Histologic Type (5) · Urogenital Diseases (5) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4) · Urogenital Neoplasms (4) · Endocrine Gland Neoplasms (3)
Anastrozole (3) · Docetaxel (3) · Gemcitabine (3) · Carboplatin (2) · Cyclophosphamide (2) · Fulvestrant (2) · Magnetic Resonance Imaging (2) · Surgical Procedures, Operative (2) · Trastuzumab (2) · eribulin (2) · ((ENB-3-isopropoxy-PIDMP)Ga(III)) (1) · 10-propargyl-10-deazaaminopterin (1) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Aryl Hydrocarbon Receptor Nuclear Translocator (1)
Washington University School of Medicine (15) · Emory University (4) · Nuvation Bio Inc. (3) · Eli Lilly and Company (2) · National Cancer Institute (NCI) (2) · Proton Collaborative Group (2) · Tata Memorial Hospital (2) · University of Arkansas (2) · Acrotech Biopharma Inc. (1) · BriaCell Therapeutics Corporation (1) · Celgene (1) · Georgetown University (1) · Infinity Pharmaceuticals, Inc. (1) · Innocrin Pharmaceutical (1) · Kaiser Permanente (1)
United States (43) · Australia (4) · France (3) · Spain (3) · Brazil (2) · Greece (2) · India (2) · Portugal (2) · Argentina (1) · Austria (1) · Canada (1) · Czechia (1) · Germany (1) · Hungary (1) · Italy (1)
Nusayba Bagegni, M.D. (2) · Andrew Chang, MD (1) · Anna Pluzanska, MD (1) · Astrid Scholten, MD, PhD (1) · Claudine Isaacs, M.D. (1) · Clive Ward-Able (1) · Daniela Ochoa, MD (1) · Deborah Farr, M.D. (1) · Elisavet Paplomata, MD (1) · Elizabeth A Salerno, Ph.D., MPH (1) · Eugen Hug, MD (1) · Foluso Ademuyiwa, MD, MPH, MSCI (1) · Garry Weems, PharmD (1)
PMID 18471751, PMID 19800452, PMID 23018481, PMID 23948301, PMID 26363985, PMID 31849532, PMID 33478260, PMID 33970392, PMID 34037241, PMID 40671809, PMID 41723535, PMID 42236089
2008 (1), P50MH122351 (1), R01AG084676 (1), R01EB002136 (1), R01HL180913 (1)